Patient selection for autoSCT in HL & increasing CR rate before autoSCT with novel salvage regimens скачать в хорошем качестве

Patient selection for autoSCT in HL & increasing CR rate before autoSCT with novel salvage regimens

Sanjal Desai, MD, University of Minnesota Medical School, Minneapolis, MN, talks on patient selection for autologous stem cell transplantation (autoSCT) in patients with Hodgkin lymphoma (HL). Since most patients with HL are young, have adequate organ function, and have a good performance status, they can be considered for autoSCT. In addition, with the advent of novel checkpoint inhibitor-based salvage regimens, an increasing number of patients achieve a complete response (CR) rate allowing them to undergo autoSCT. Nevertheless, patients who are ineligible for autoSCT due to age and comorbidities remain a significant unmet medical need. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.